BIOMAT Database Logo BIOMAT Database Logo

Cerebrospinal fluid HIV-1 virological escape with lymphocytic meningitis under lopinavir/ritonavir monotherapy. 2010

Pierre de Truchis, and Dominique Mathez, and Emuri Abe, and Aurelien Dinh, and Damien Ledu, and Alix Greder-Belan, and Jean-Claude Alvarez

UI MeSH Term Description Entries
D008587 Meningitis, Viral Viral infections of the leptomeninges and subarachnoid space. TOGAVIRIDAE INFECTIONS; FLAVIVIRIDAE INFECTIONS; RUBELLA; BUNYAVIRIDAE INFECTIONS; ORBIVIRUS infections; PICORNAVIRIDAE INFECTIONS; ORTHOMYXOVIRIDAE INFECTIONS; RHABDOVIRIDAE INFECTIONS; ARENAVIRIDAE INFECTIONS; HERPESVIRIDAE INFECTIONS; ADENOVIRIDAE INFECTIONS; JC VIRUS infections; and RETROVIRIDAE INFECTIONS may cause this form of meningitis. Clinical manifestations include fever, headache, neck pain, vomiting, PHOTOPHOBIA, and signs of meningeal irritation. (From Joynt, Clinical Neurology, 1996, Ch26, pp1-3) Viral Meningitis,Meningitides, Viral,Viral Meningitides
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D061466 Lopinavir An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A. A-157378.0,ABT 378,ABT-378,N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide,A 157378.0,A157378.0,ABT378
D019438 Ritonavir An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A. ABT 538,ABT-538,Norvir,ABT538

Related Publications

Pierre de Truchis, and Dominique Mathez, and Emuri Abe, and Aurelien Dinh, and Damien Ledu, and Alix Greder-Belan, and Jean-Claude Alvarez
Incorrect attribution of cerebrospinal fluid HIV-1 virological escape and lymphocytic meningitis to lopinavir/ritonavir monotherapy.
September 2010, AIDS (London, England),
Pierre de Truchis, and Dominique Mathez, and Emuri Abe, and Aurelien Dinh, and Damien Ledu, and Alix Greder-Belan, and Jean-Claude Alvarez
Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients.
August 2013, Antimicrobial agents and chemotherapy,
Pierre de Truchis, and Dominique Mathez, and Emuri Abe, and Aurelien Dinh, and Damien Ledu, and Alix Greder-Belan, and Jean-Claude Alvarez
Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
January 2004, Scandinavian journal of infectious diseases,
Pierre de Truchis, and Dominique Mathez, and Emuri Abe, and Aurelien Dinh, and Damien Ledu, and Alix Greder-Belan, and Jean-Claude Alvarez
Monotherapy with lopinavir/ritonavir.
May 2007, Expert opinion on investigational drugs,
Pierre de Truchis, and Dominique Mathez, and Emuri Abe, and Aurelien Dinh, and Damien Ledu, and Alix Greder-Belan, and Jean-Claude Alvarez
Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression.
October 2014, AIDS research and human retroviruses,
Pierre de Truchis, and Dominique Mathez, and Emuri Abe, and Aurelien Dinh, and Damien Ledu, and Alix Greder-Belan, and Jean-Claude Alvarez
Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.
January 2013, PloS one,
Pierre de Truchis, and Dominique Mathez, and Emuri Abe, and Aurelien Dinh, and Damien Ledu, and Alix Greder-Belan, and Jean-Claude Alvarez
[Prognostic factors of virological response in patients treated with lopinavir/ritonavir monotherapy].
December 2008, Enfermedades infecciosas y microbiologia clinica,
Pierre de Truchis, and Dominique Mathez, and Emuri Abe, and Aurelien Dinh, and Damien Ledu, and Alix Greder-Belan, and Jean-Claude Alvarez
Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children.
January 2004, AIDS (London, England),
Pierre de Truchis, and Dominique Mathez, and Emuri Abe, and Aurelien Dinh, and Damien Ledu, and Alix Greder-Belan, and Jean-Claude Alvarez
HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
January 2014, Antiviral therapy,
Pierre de Truchis, and Dominique Mathez, and Emuri Abe, and Aurelien Dinh, and Damien Ledu, and Alix Greder-Belan, and Jean-Claude Alvarez
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
January 2008, AIDS (London, England),
Copied contents to your clipboard!